Sept 16 (Reuters) - Tonix Pharmaceuticals Holding Corp
:
* TONIX PHARMACEUTICALS ANNOUNCES THAT ITS SINGLE DOSE MPOX VACCINE CANDIDATE TNX-801 ALIGNS WITH WHO’S NEWLY ISSUED PREFERRED TARGET PRODUCT PROFILE FOR MPOX VACCINES IN GLOBAL HEALTH EMERGENCY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments